Plasma α-L-fucosidase-1 in patients with Sjögren's syndrome and other rheumatic disorders.
Sjögren syndrome
pediatric population
plasma rheumatoid arthritis
α-L-FUCA-1
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
12
11
2018
revised:
02
05
2019
accepted:
23
05
2019
pubmed:
17
8
2019
medline:
20
2
2020
entrez:
17
8
2019
Statut:
ppublish
Résumé
Human α-fucosidase (EC 3.2.1.51) is a hydrolase the importance of which has been increasing in the latest years. However, data about its plasma level in children with autoimmune disorders, particularly Sjögren's syndrome (SS), are lacking. In this study, the plasma activity of L-α-fucosidase-1 (α-L-FUCA-1) was assayed in hospitalized children and adults and its association with SS and other rheumatic disorders further evaluated. In total 73 Hungarian hospitalized patients, 32 children (2.5-10 years) and 41 adults (32-68 years), were enrolled in the study and underwent plasma assay of α-L-FUCA1 activity. Linear regression, Durbin-Watson (DW), and Pearson tests were evaluated to investigate the relationship between α-L-FUCA-1 plasma levels and autoimmune manifestations. α-L-FUCA-1 correlated with SS both in children (2-sided t test, P = 0.0023) and in adults (2-sided t test, P = 0.00035). Linear regressions showed that in other rheumatic disorders, α-L-FUCA1 did not show any differential distribution related to the particular pathology (r = 0.2042, P = 0.1531, DW test = 2.2139 positive), while this trend was radically opposite for patients with SS (r = 0.1462, P = 0.0032, DW test = 1.3664, negative). Alterations in plasma level of α-L-FUCA-1 were significantly associated with SS. This preliminary result should encourage further research on α-L-FUCA-1 as a possible differential serological marker of SS.
Sections du résumé
BACKGROUND
BACKGROUND
Human α-fucosidase (EC 3.2.1.51) is a hydrolase the importance of which has been increasing in the latest years. However, data about its plasma level in children with autoimmune disorders, particularly Sjögren's syndrome (SS), are lacking. In this study, the plasma activity of L-α-fucosidase-1 (α-L-FUCA-1) was assayed in hospitalized children and adults and its association with SS and other rheumatic disorders further evaluated.
METHODS
METHODS
In total 73 Hungarian hospitalized patients, 32 children (2.5-10 years) and 41 adults (32-68 years), were enrolled in the study and underwent plasma assay of α-L-FUCA1 activity. Linear regression, Durbin-Watson (DW), and Pearson tests were evaluated to investigate the relationship between α-L-FUCA-1 plasma levels and autoimmune manifestations.
RESULTS
RESULTS
α-L-FUCA-1 correlated with SS both in children (2-sided t test, P = 0.0023) and in adults (2-sided t test, P = 0.00035). Linear regressions showed that in other rheumatic disorders, α-L-FUCA1 did not show any differential distribution related to the particular pathology (r = 0.2042, P = 0.1531, DW test = 2.2139 positive), while this trend was radically opposite for patients with SS (r = 0.1462, P = 0.0032, DW test = 1.3664, negative).
CONCLUSIONS
CONCLUSIONS
Alterations in plasma level of α-L-FUCA-1 were significantly associated with SS. This preliminary result should encourage further research on α-L-FUCA-1 as a possible differential serological marker of SS.
Identifiants
pubmed: 31419081
doi: 10.1111/1756-185X.13639
doi:
Substances chimiques
Biomarkers
0
FUCA1 protein, human
0
alpha-L-Fucosidase
EC 3.2.1.51
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1762-1767Informations de copyright
© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Zhang S-Y, Lin B-D, Li B-R. Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma. FEBS open bio. 2015;5:240-244.
Gan Y, Liang Q, Song X. Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis. Tumour Biol. 2014;35(5):3953-3960.
Michalski J-C, Klein A. Glycoprotein lysosomal storage disorders: α-and β-mannosidosis, fucosidosis and α-N-acetylgalactosaminidase deficiency. Biochim Biophys Acta Mol Basis Dis. 1999;455(2-3):69-84.
Muthusamy K, Thomas MM, George RE, Alexander M, Mani S, Benjamin RN. Siblings with fucosidosis. J Pediatr Neurosci. 2014;9(2):156.
Shaukat R, Raza SM, Yuns ZM, Omar A, Afroze B. Alpha-fucosidosis-Two brothers presenting with dysostosis multiplex. Egypt J Med Hum Genet. 2016;17(3):243-246.
Sobkowicz AD, Gallagher ME, Reid CJ, Crean D, Carrington SD, Irwin JA. Modulation of expression in BEAS-2B airway epithelial cells of α-L-fucosidase A1 and A2 by Th1 and Th2 cytokines, and overexpression of α-L-fucosidase 2. Mol Cell Biochem. 2014;390(1-2):101-113.
Yokogawa N, Lieberman S, Sherry D, Vivino F. Features of childhood Sjögren's syndrome in comparison to adult Sjögren's syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol. 2016;34(2):343-351.
Takei S. Sjögren's syndrome (SS) in childhood: is it essentially different from adult SS? Nihon Rinsho Meneki Gakkai Kaishi. 2010;33(1):8-14.
Moy MM, Mandel L. Identifying primary sjögren syndrome in children: case report. J Oral Maxillofac Surg. 2014;72(12):2485-2490.
Mannion ML, Beukelman T. What is the background incidence of malignancy in children with rheumatic disease? Curr Rheumatol Rep. 2013;15(3):310.
Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy? is there an association? Scand J Rheumatol. 2001;30(4):185-188.
Hilário M, Len CA, Roja SC, Terreri MT, Almeida G, Andrade L. Frequency of antinuclear antibodies in healthy children and adolescents. Clin Pediatr (Phila). 2004;43(7):637-642.
Wananukul S, Voramethkul W, Kaewopas Y, Hanvivatvong O. Prevalence of positive antinuclear antibodies in healthy children. Asian Pac J Allergy Immunol. 2005;23(2-3):153.
Ali S, Jenkins Y, Kirkley M, et al. Leukocyte extravasation: an immunoregulatory role for α-l-fucosidase? J Immunol. 2008;181(4):2407-2413.
Török M, Berta A, Serfözö J. Beziehungen zwischen den morphologischen Veränderungen der Bindehaut und den Veränderungen in der Zusammensetzung der Tränenglykoproteine im Sjögren-Syndrom. Fortschritte der Ophthalmologie: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 1986;83(3):290-292.
Scanlin TF, Glick MC. Terminal glycosylation in cystic fibrosis. Biochim Biophys Acta Mol Basis Dis. 1999;1455(2-3):241-253.
Durand P, Gatti R, Borrone C, et al. Detection of carriers and prenatal diagnosis for fucosidosis in Calabria. Hum Genet. 1979;51(2):195-201.
Inui K, Akagi M, Nishigaki T, Muramatsu T, Tsukamoto H, Okada S. A case of chronic infantile type of fucosidosis: clinical and magnetic resonance image findings. Brain Dev. 2000;22(1):47-49.
Jiang M, Liu S, Jiang H, et al. Brain abnormalities in fucosidosis: transplantation or supportive therapy? Metab Brain Dis. 2017;32(2):317-320.
Junna Z, Gongde C, Jinying X, Xiu Z. Serum AFU, 5'-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis. Open Med (Wars). 2017;12:354-358.
Kumar KJ, Kudakesseril AS, Sheeladevi CS, Sowmya HV. Primary sjogrens syndrome in a child. Iran J Pediatr. 2015;25(2):e254.
Rasmussen A, Radfar L, Lewis D, et al. Previous diagnosis of Sjögren s syndrome as rheumatoid arthritis or systemic lupus erythematosus. Rheumatology (Oxford). 2016;55(7):1195-1201.
Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S. The complexity of Sjögren's syndrome: novel aspects on pathogenesis. Immunol Lett. 2011;141(1):1-9.
Brito-Zerón P, Theander E, Baldini C, et al. Early diagnosis of primary Sjögren s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol. 2016;12(2):137-156.
Mirouse A, Seror R, Vicaut E, et al. Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study. Autoimmun Rev. 2018;18(1):9-14.
Megson ZA, Messner P, Schäffer C. Assaying fucosidase activity. Methods Mol Biol. 1954;2019:269-278.
Bonin S, Parascandolo A, Aversa C, et al. Reduced expression of α-L-Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients. Oncotarget. 2018;9(20):15228.
Ezawa I, Sawai Y, Kawase T, et al. Novel p53 target gene FUCA 1 encodes a fucosidase and regulates growth and survival of cancer cells. Cancer Sci. 2016;107(6):734-745.
Ge W, Li D, Gao Y, Cao X. The roles of lysosomes in inflammation and autoimmune diseases. Int Rev Immunol. 2015;34(5):415-431.
Perl A. Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren s syndrome. Curr Opin Rheumatol. 2009;21(5):443.
Dong S, Chang Y, Shen J, Xue C, Chen F. Purification, expression and characterization of a novel α-l-fucosidase from a marine bacteria Wenyingzhuangia fucanilytica. Protein Expr Purif. 2017;129:9-17.
Aramesh M, Ajoudanifar H. Alkaline protease producing Bacillus isolation and identification from Iran. Banat's J Biotechnol. 2017;8:140-147.
Barazesh F, Oloumi H, Nasibi F, Kalantari KM, Nasibi F, Kalantari KM. Effect of spermine, epibrassinolid and their interaction on inflorescence buds and fruits abscission of pistachio tree (Pistacia vera L.), "Ahmad-Aghai" cultivar. Banat's J Biotechnol. 2017;8(16):105-115.
Dadkhah A, Rad A, Azizinezhad R. Effect of pumpkin powder as a fat replacer on rheological properties, specific volume and moisture content of cake. Banat's J Biotechnol. 2017;8(16):116-126.
Eed AM, Burgoyne AH. Tissue culture of Simmondsia chinensis (Link) Schneider. Banat's J Biotechnol. 2015;6(11):45-53.
Egu UN, Okonkwo JC. Effect of gonadotrophin (diclair (R)) on semen characteristics, hormonal profile and biochemical constituents of the seminal plasma of mature balami rams. Banat's J Biotechnol. 2017;8(15):90-97.
Endreffy I, Bjørklund G, Szerafin L, Chirumbolo S, Urbina MA, Endreffy E. Plasma alpha-L-fucosidase activity in chronic inflammation and autoimmune disorders in a pediatric cohort of hospitalized patients. Immunol Res. 2017;65(5):1025-1030.